[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer for patients (2024 edition)].

Lung cancer, a malignant tumor remaining high incidence and mortality rates in China and globally, places huge burdens to families and the public healthcare system. In order to improve the diagnosis and treatment of lung cancer, enhance patients' knowledge of the disease, promote evidence-based guidelines to patients, and facilitate shared decision-making, the Chinese Medical Association convened multidisciplinary experts, patients, and public representatives to develop the Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer for patients. The guideline selected most concerned issues, drew on information from domestic and international guidelines, latest research findings, and clinical experience of lung cancer, and combined them with current clinical practices in China and patients' needs. This guideline aims to provide comprehensive, scientific, and practical information on lung cancer diagnosis and treatment for patients and their families, help them further understanding the basic knowledge, diagnosis and treatment process, treatment methods, and prognosis management of lung cancer, enhance the self-management ability of patients, and raise the public awareness and participation in lung cancer prevention and treatment.

Publication Details

Journal
PubMed
Published
2025-01-23
DOI
https://doi.org/10.3760/cma.j.cn112152-20241024-00464
Citations
1
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer for patients (2024 edition)].

1 citations
PubMed
Lung Cancer Treatments and Mutations
1.52
article

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer for patients (2024 edition)].

article en
1 citations

Abstract

Lung cancer, a malignant tumor remaining high incidence and mortality rates in China and globally, places huge burdens to families and the public healthcare system. In order to improve the diagnosis and treatment of lung cancer, enhance patients' knowledge of the disease, promote evidence-based guidelines to patients, and facilitate shared decision-making, the Chinese Medical Association convened multidisciplinary experts, patients, and public representatives to develop the Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer for patients. The guideline selected most concerned issues, drew on information from domestic and international guidelines, latest research findings, and clinical experience of lung cancer, and combined them with current clinical practices in China and patients' needs. This guideline aims to provide comprehensive, scientific, and practical information on lung cancer diagnosis and treatment for patients and their families, help them further understanding the basic knowledge, diagnosis and treatment process, treatment methods, and prognosis management of lung cancer, enhance the self-management ability of patients, and raise the public awareness and participation in lung cancer prevention and treatment.

PubMedVol. 47(1)
Openalex Percentile: Top 23%
Lung Cancer Treatments and Mutations
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer for patients (2024 edition)]. · PubMed (2025) | TGRS Research Map | TGRS